Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value and an activist investor is agitating for change.

Notably, Pfizer said it expects demand for its Covid shot to drop 29% to about 65 million doses in 2023, as the U.S. federal government plans to stop funding the shot as it prepares to end the ...

The primary goal of Pfizer’s COVID-19 vaccine was not to prevent transmission, nor was that a requirement for its initial authorization in both the U.S. and Europe.

Pfizer struck a $43 billion deal for Seagen to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition ...

The primary goal of Pfizer’s COVID-19 vaccine was not to prevent transmission, nor was that a requirement for its initial authorization in both the U.S. and Europe.